FGF2 and fibrosarcoma: Similar to the breast cancer model, anti-VEGF and imatinib combination markedly induced cellular apoptosis in FGF-2+ fibrosarcomas, which otherwise were completely resistant in their monotherapy settings (Fig. 5d–f).